08 Mar 2022
Lonza Expands API Development and Manufacturing Laboratories in Nansha, China
  • The development and cGMP manufacturing laboratories will support the global operations network and provide additional early-phase highly-potent API manufacturing capabilities
  • The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers

Basel, Switzerland, 8 March 2022 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced the completion of a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China. The expansion focused on extending the capabilities and capacity of development laboratories and kilogram-scale cGMP manufacturing laboratories for clinical supply of highly-potent APIs (HPAPI).

HPAPIs represent a growing part of the small molecules pipeline with special requirements related to equipment, process safety, containment, and facility design. HPAPIs currently form a large part of Lonza’s small molecule development pipeline and the demand for manufacturing is growing. The new laboratories are part of the recent investment to expand the mid-scale manufacturing capacity at the Nansha (CN) site and add additional capabilities in Lonza’s global HPAPI manufacturing network to meet growing customer demand.

Jan Vertommen, Executive Director, Commercial Development, Small Molecules, Lonza commented: “With over 1000 HPAPIs in development across multiple indications, there is a growing need for HPAPI development and manufacturing capacity from early-phase to commercial. The new laboratories further strengthen our global HPAPI manufacturing offering, and we are pleased that the first European and US-headquartered customers have signed HPAPI programs for our new laboratories in Nansha.”

The laboratory capabilities will increase the laboratory footprint to 250 m2 and will be equipped with state-of-the-art analytical and manufacturing equipment. The new laboratories will begin operations in March 2022.

Jason Zhang, R&D Director, Small Molecules API, Lonza, added: “The expansion of our HPAPI capabilities at Nansha enables us to enter HPAPI manufacturing to meet growing global demand, especially in supporting clinical trials in oncology. Our presence in Nansha allows us to leverage world-class, high-quality and reliable local suppliers of raw materials, thus further increasing the speed of problem-solving and manufacturing.”

The expanded capabilities at the Nansha site will continue to support the development and manufacture of innovative treatments for our global customers and their patients. For more information on Lonza’s active pharmaceutical ingredients and intermediates offering at Nansha, China, visit https://pharma.lonza.com/about/locations/nansha-china.